What are the limitations of China's new drug development system exposed in the new crown epidemic?

Medicine son, May 27 (Upi) -- At this stage, so much hope is pinned on Redcieway, reflecting the failure, not success, of our new drug development systemIt is a classic example of why we need a new model of drug development that is not limited by the current market economy model to respond to epidemicoutbreaks and other neglected infectious diseases (Neglected Infectious Diseases, NID)since 2002, such as Severe Acute Respiratory Syndrome (SARS) (2002-2003), Swine Flu (H1N1) (2009-2010), Middle East Respiratory Syndrome (MERS) (2015, 2016, 20 18), The Zika virus (2015-2016), the Ebola virus (2014, 2017, 2018, 2019) and other epidemics have caused nearly 600,000 deaths around the world, the world has invested a lot of human and material resources to treat, prevent and recoverHowever, in the wake of these devastating outbreaks, the pharmaceutical industry has been unable to insist on investment in new treatments and related vaccines, despite clear warnings from academia, business and others that another pandemic is likelyso that in late 2019, the Covid-19 was caught off guardfrom the Covid-19 pandemic, the pharmaceutical industry is responding to a full response to save people from global catastrophesAbbott's new coronavirus rapid detection technology has won him enthusiastic acclaim, and after decades of profiteering from the opioid crisis, Johnson and Johnson has even aired an eight-episode reality show to boost its campaign for a new corona vaccine research projectBut this is not a situation for an industry that has long known that another pandemic could occur but has only now made meaningful investments in researchthis may surprise the general public, but in today's capital-driven market, investing in pandemic preparedness and NIDs such as tuberculosis and malaria is not, and has never been, a priority for drug companies, even though these diseases cause more than 2 million deaths each year, almost seven times as many as covid-19 deaths so fara disconnect between public health needs and market behaviour in pharmaceutical companies for several reasonsOne is that outbreaks are unpredictable and may sometimes not last long enough to create enough markets for a new treatment, and that diseases such as malaria and Ebola are mainly affecting poor people in low-income areas such as Africa, which do not constitute a lucrative marketinvest in new treatments to address potential pandemic threats, or buy back shares to boost share prices and generate more revenue? Drug makers are likely to choose the latter, just as there are common rules in other industries - higher shareholder profits, executive pay, rather than investing in new products, services or employeesin 2018, global funding for NID research and drug development will be only $4 billion, of which 64 percent comes from public taxes, 19 percent from charitable organizations, pharmaceutical companies contribute only 17 percent, or $650 million, and combined with the concept of global TOP20 pharmaceutical companies with total revenueof more than $612 billion in 2018 and $650 million in real drug revenueglobalcompany's TOP20 revenue list in 2018in fact, the pharmaceutical industry's investment is limited to NID and pandemic prevention Earlier this year, WHO issued a report saying that the fight against drug-resistant infections was being weakened by falling investment and a lack of innovation in new antibiotic research The continued withdrawal of large pharmaceutical companies from the field, driven mainly by small and medium-sized , has led to a serious shortage of new antibiotics Most of the 50 antibiotics currently in clinical trials are limited to existing antibiotics, while only two are resistant to gram-negative bacteria with multiple resistance In addition, these products are still in the early stages of development, the most optimistic situation is only about 10 years to have 2-5 products on the market pandemic, NID, drug-resistant infections, and so on, are already pressing for global health crises, the fact is that many pharmaceutical companies are more inclined to spend time researching how to keep existing drugs patented longer than those that are really important to human health, for example by filing hundreds of patents for a drug under the guise of pharmaceutical innovation to prevent genericdrugs from dividing the market and thus driving up prices in an analysis of patent applications for 12 of the best-selling drugs in the United States, researchers noted that, on average, there were 125 patent applications and 71 patents granted for each drug
; 　　The model of drug development, which is mainly restricted by market economy orientation, clearly does not apply to the response to the human public health crisis If we are prepared to take this seriously and prepare seriously for potential future epidemics, NIDs, drug-resistant infections, and so on, we need a new economic model of drug development that does not rely on market privileges First, we need to conduct existing research in a more open and transparent manner, even if some of it is protected by intellectual property The pharmaceutical industry is sitting on numerous patents and research developments, but unless there are opportunities in the market, many of them will be difficult to continue, and a more open scientific platform could earlier stimulate broader research engagement, saving time and deepening drug research , for example, the company recently announced that it is exploring the development of an oral or inhaled form of Ridsiewe to replace the intravenous infusions currently required in , and that if Gilead could cooperate earlier and more widely, scientists could explore the feasibility of a form of drug delivery, making drug use easier and easier for the poor to access second, there should be no over-reliance on the "private" part of the PPP The current situation is that the government invests heavily in hospitals, enterprises and other to pay for the research and treatment of new coronary pneumonia, but in the end, these knowledge, research results may enter the public health-oriented private pharmaceutical enterprises Therefore, it is a feasible strategy to invest more, build the scientific research ability and transformation ability of "public" and turn basic research into a practical final to solve the urgent public health problems that may be faced Maybe before the next big pop, we can start preparing in addition, over the past 40 years, intellectual property awareness has expanded rapidly around the world, which has led to a prolonged market monopoly and increasing privatization of scientific research in the pharmaceutical industry, and perhaps the exploration of new intellectual property systems that are more suitable for modern drug market competition and new drug research and development.